Anupam Rasayan India Ltd., one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter ended March 31, 2025.

For the year ended March 31, 2025, Anupam Rasayan has posted consolidated total revenue of Rs. 1,448.5 crore as compared to Rs. 1,505.3 crore in FY24; down 4% YoY. EBITDA (incl. other income) was at Rs. 412.3 crore in FY25 as compared to Rs. 410.9 crore in FY24, this would translate into 28% EBITDA margin in FY25. Profit After Tax was at Rs. 160 crore in FY25 as compared to Rs. 167.4 crore in FY24.

For the quarter ended March 31, 2025, Anupam Rasayan India reported total revenue for of Rs. 505.7 crore as compared to Rs. 413 crore in Q4 FY24; up 22% YoY. EBITDA (incl. other income) was at Rs. 150 crore in Q4 FY25 as compared to Rs. 104.7 crore in Q4 FY24, up 43% and this would translate into 30% EBITDA margin in this quarter. Profit After Tax was at Rs. 62.9 crore in Q4 FY25 as compared to Rs. 40.5 crore in Q4FY24; up 56% YoY.

Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “Consolidated revenue for the quarter Q4 FY25 stood at Rs. 506 crores registering a growth of 22% YoY and 31% QoQ. Consolidated revenue for the full year FY25 stood at Rs. 1,448 crores registering a degrowth of 4% YoY. This performance was supported by growth in pharma and polymer coupled with strong performance from Tanfac. Margins have remained consistent this quarter, reflecting our focus on operational efficiency and a favourable product mix.

While H1 FY25 was subdued due to weak macro conditions, I am pleased to share that H2 has shown clear signs of recovery — particularly in Q4 FY25 where we have seen meaningful improvement with sales increasing both year- on-year and sequentially. We remain confident in our ability to return to the historical growth rates achieved prior to the recent slowdown.”